{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:45:58Z","timestamp":1794566758585,"version":"4.9.1"},"reference-count":62,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In chronic-phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib, failure to achieve early molecular response (EMR; EMR failure: BCR-ABL1 &amp;gt;10% on the international scale at 3 months) is predictive of inferior outcomes. Identifying patients at high-risk of EMR failure at diagnosis provides an opportunity to intensify frontline therapy and potentially avoid EMR failure. We studied blood samples from 96 CP-CML patients at diagnosis and identified 365 genes that were aberrantly expressed in 13 patients who subsequently failed to achieve EMR, with a gene signature significantly enriched for stem cell phenotype (eg, Myc, \u03b2-catenin, Hoxa9\/Meis1), cell cycle, and reduced immune response pathways. We selected a 17-gene panel to predict EMR failure and validated this signature on an independent patient cohort. Patients classified as high risk with our gene expression signature (HR-GES) exhibited significantly higher rates of EMR failure compared with low-risk (LR-GES) patients (78% vs 5%; P &amp;lt; .0001), with an overall accuracy of 93%. Furthermore, HR-GES patients who received frontline nilotinib had a relatively low rate of EMR failure (10%). However, HR-GES patients still had inferior deep molecular response achievement rate by 24 months compared with LR-GES patients. This novel multigene signature may be useful for selecting patients at high risk of EMR failure on standard therapy who may benefit from trials of more potent kinase inhibitors or other experimental approaches.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000195","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T20:45:15Z","timestamp":1558730715000},"page":"1610-1621","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-7852","authenticated-orcid":false,"given":"Chung H.","family":"Kok","sequence":"first","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Lu","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale B.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara M.","family":"Leclercq","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Dang","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verity A.","family":"Saunders","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Alfred Health and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-333X","authenticated-orcid":false,"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"Discipline of Medicine, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"issue":"10","key":"2020021108292965100_B1","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2020021108292965100_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia [published correction appears in Leukemia. 2010;24(5):1102]","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"2020021108292965100_B3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","article-title":"Which TKI? An embarrassment of riches for chronic myeloid leukemia patients","volume":"2013","author":"Hughes","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"2020021108292965100_B4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021108292965100_B5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021108292965100_B6","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021108292965100_B7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020021108292965100_B8","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2020021108292965100_B9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","article-title":"Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia","volume":"55","author":"Jabbour","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020021108292965100_B10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020021108292965100_B11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2020021108292965100_B12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2020021108292965100_B13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"2020021108292965100_B14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2020021108292965100_B15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2020021108292965100_B16","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"issue":"29","key":"2020021108292965100_B17","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","article-title":"European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation","volume":"29","author":"Marin","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021108292965100_B18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2020021108292965100_B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2020021108292965100_B20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020021108292965100_B21","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"issue":"22","key":"2020021108292965100_B22","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021108292965100_B23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach","volume":"20","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"2020021108292965100_B24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients","volume":"20","author":"Frank","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"2020021108292965100_B25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1349-7006.2002.tb01328.x","article-title":"Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis","volume":"93","author":"Kaneta","year":"2002","journal-title":"Jpn J Cancer Res"},{"issue":"7","key":"2020021108292965100_B26","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2020021108292965100_B27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.14829","article-title":"Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd","volume":"179","author":"Hughes","year":"2017","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2020021108292965100_B28","article-title":"Nilotinib in combination with pegylated interferon alfa-2b for CP-CML leads to high molecular response rates: interim results of the Pinnacle study [abstract]","volume":"130","author":"Yeung","year":"2017","journal-title":"Blood"},{"key":"2020021108292965100_B29","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"22","key":"2020021108292965100_B30","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1093\/nar\/gkq871","article-title":"Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips","volume":"38","author":"Shi","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2020021108292965100_B31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"10","key":"2020021108292965100_B32","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"issue":"43","key":"2020021108292965100_B33","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2020021108292965100_B34","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1093\/bioinformatics\/btp578","article-title":"HTqPCR: high-throughput analysis and visualization of quantitative real-time PCR data in R","volume":"25","author":"Dvinge","year":"2009","journal-title":"Bioinformatics"},{"key":"2020021108292965100_B35","author":"Chen"},{"key":"2020021108292965100_B36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1613\/jair.953","article-title":"SMOTE: synthetic minority over-sampling technique","volume":"16","author":"Chawla","year":"2002","journal-title":"J Artif Intell Res"},{"key":"2020021108292965100_B37","article-title":"Data Mining With R, Learning With Case Studies","author":"Torgo","year":"2010"},{"issue":"3","key":"2020021108292965100_B38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2013.329","article-title":"Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients","volume":"28","author":"Kok","year":"2014","journal-title":"Leukemia"},{"issue":"446","key":"2020021108292965100_B39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2020021108292965100_B40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/asheducation-2014.1.240","article-title":"Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"2014","author":"Yeung","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7647","key":"2020021108292965100_B41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"26","key":"2020021108292965100_B42","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2020021108292965100_B43","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"6871","key":"2020021108292965100_B44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van \u2019t Veer","year":"2002","journal-title":"Nature"},{"issue":"6","key":"2020021108292965100_B45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1172\/JCI20032","article-title":"Gene expression profiling predicts clinical outcome of prostate cancer","volume":"113","author":"Glinsky","year":"2004","journal-title":"J Clin Invest"},{"issue":"5","key":"2020021108292965100_B46","doi-asserted-by":"crossref","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","article-title":"Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value","volume":"10","author":"Marisa","year":"2013","journal-title":"PLoS Med"},{"issue":"9","key":"2020021108292965100_B47","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1200\/JCO.2012.44.3184","article-title":"Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021108292965100_B48","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat Med"},{"issue":"10","key":"2020021108292965100_B49","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/leu.2013.181","article-title":"A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia","volume":"27","author":"Metzeler","year":"2013","journal-title":"Leukemia"},{"issue":"26","key":"2020021108292965100_B50","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2020021108292965100_B51","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020021108292965100_B52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/CLK.2007.n.014","article-title":"Gene expression profile of chronic myeloid leukemia innately resistant to imatinib","volume":"1","author":"Cammarata","year":"2007","journal-title":"Clin Leuk"},{"issue":"8","key":"2020021108292965100_B53","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7633","key":"2020021108292965100_B54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"22","key":"2020021108292965100_B55","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2013-04-497040","article-title":"BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein","volume":"124","author":"Agarwal","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020021108292965100_B56","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med"},{"issue":"11","key":"2020021108292965100_B57","first-page":"1487","article-title":"Insulin-like growth factor binding protein-2 regulates \u03b2-catenin signaling pathway in glioma cells and contributes to poor patient prognosis","volume":"18","author":"Patil","year":"2016","journal-title":"Neuro-oncol"},{"issue":"12","key":"2020021108292965100_B58","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2011-01-331876","article-title":"IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells","volume":"118","author":"Huynh","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020021108292965100_B59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbrc.2010.05.145","article-title":"IGFBP2 promotes glioma tumor stem cell expansion and survival","volume":"397","author":"Hsieh","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2020021108292965100_B60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1756-8722-6-72","article-title":"IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells","volume":"6","author":"Chen","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2020021108292965100_B61","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.leukres.2011.08.006","article-title":"High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia","volume":"35","author":"K\u00fchnl","year":"2011","journal-title":"Leuk Res"},{"issue":"12","key":"2020021108292965100_B62","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1535-7163.MCT-13-0233","article-title":"IGFBP2\/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells","volume":"12","author":"Lu","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/10\/1610\/1632365\/advancesadv2019000195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/10\/1610\/1632365\/advancesadv2019000195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:46:54Z","timestamp":1721321214000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/10\/1610\/246652\/Gene-expression-signature-that-predicts-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000195","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]}}}